• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by INNOVATE Corp. (Amendment)

    1/4/23 4:27:09 PM ET
    $VATE
    Metal Fabrications
    Industrials
    Get the next $VATE alert in real time by email
    SC 13D/A 1 sc13da1013108001_01042023.htm AMENDMENT NO. 10 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 10)1

    Innovate Corp.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    404139107

    (CUSIP Number)

    MICHAEL GORZYNSKI

    595 Madison Avenue, 29th Floor

    New York, NY 10022

    (646) 274-9610

     

    ANDREW FREEDMAN, ESQ.

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    December 30, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 404139107

      1   NAME OF REPORTING PERSON  
             
            PERCY ROCKDALE LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            MICHIGAN  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         5,048,755  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              5,048,755  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            5,048,755  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.4% *  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * The aggregate percentage of shares of Common Stock reported owned herein is based upon 78,355,954 shares outstanding, as of October 31, 2022, which is the total number of shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022.

    2

    CUSIP No. 404139107

      1   NAME OF REPORTING PERSON  
             
            RIO ROYAL LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            MICHIGAN  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         24,462  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              24,462  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            24,462  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1% *  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * The aggregate percentage of shares of Common Stock reported owned herein is based upon 78,355,954 shares outstanding, as of October 31, 2022, which is the total number of shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022.

    3

    CUSIP No. 404139107

     

      1   NAME OF REPORTING PERSON  
             
            MG CAPITAL MANAGEMENT LTD.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CAYMAN ISLANDS  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         24,462  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              24,462  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            24,462  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1% *  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    * The aggregate percentage of shares of Common Stock reported owned herein is based upon 78,355,954 shares outstanding, as of October 31, 2022, which is the total number of shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022.

    4

    CUSIP No. 404139107

     

      1   NAME OF REPORTING PERSON  
             
            MICHAEL GORZYNSKI  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         56,303  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         8,713,113 *  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              56,303  
        10   SHARED DISPOSITIVE POWER  
               
              8,713,113 *  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            8,769,416  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            10.7% **  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    * Including (i) 6,125 shares of Series A-3 Convertible Preferred Stock (the “Series A-3 Convertible Preferred Stock”), which are convertible into 1,764,357 shares of Common Stock and (ii) 10,000 shares of Series A-4 Convertible Preferred Stock (the “Series A-4 Convertible Preferred Stock”), which are convertible into 1,875,539 shares of Common Stock, as further described in Item 5.

     

    ** The aggregate percentage of shares of Common Stock for the Continental Reporting Persons and Mr. Gorzynski reported herein is based upon 81,995,850 shares of Common Stock, which reflects the sum of (i) 78,355,954 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022, plus (ii) 3,639,896 shares of Common Stock issuable upon the conversion of the Series A-3 and Series A-4 Convertible Preferred Stock beneficially owned by the Continental Reporting Persons, as described in Item 5.

    5

    CUSIP No. 404139107

     

      1   NAME OF REPORTING PERSON  
             
            CONTINENTAL GENERAL INSURANCE COMPANY  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            TEXAS  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,639,896 *  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              3,639,896 *  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,639,896 *  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            4.4% **  
      14   TYPE OF REPORTING PERSON  
             
            CO  

      

    * Consisting of (i) 6,125 shares of Series A-3 Convertible Preferred Stock, which are convertible into 1,764,357 shares of Common Stock and (ii) 10,000 shares of Series A-4 Convertible Preferred Stock, which are convertible into 1,875,539 shares of Common Stock, as further described in Item 5.

     

    ** The aggregate percentage of shares of Common Stock for the Continental Reporting Persons and Mr. Gorzynski reported herein is based upon 81,995,850 shares of Common Stock, which reflects the sum of (i) 78,355,954 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022, plus (ii) 3,639,896 shares of Common Stock issuable upon the conversion of the Series A-3 and Series A-4 Convertible Preferred Stock beneficially owned by the Continental Reporting Persons, as described in Item 5.

    6

    CUSIP No. 404139107

     

      1   NAME OF REPORTING PERSON  
             
            CONTINENTAL LTC, INC.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,639,896 *  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              3,639,896 *  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,639,896 *  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            4.4% **  
      14   TYPE OF REPORTING PERSON  
             
            CO  

      

    * Consisting of (i) 6,125 shares of Series A-3 Convertible Preferred Stock, which are convertible into 1,764,357 shares of Common Stock and (ii) 10,000 shares of Series A-4 Convertible Preferred Stock, which are convertible into 1,875,539 shares of Common Stock, as further described in Item 5.

     

    ** The aggregate percentage of shares of Common Stock for the Continental Reporting Persons and Mr. Gorzynski reported herein is based upon 81,995,850 shares of Common Stock, which reflects the sum of (i) 78,355,954 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022, plus (ii) 3,639,896 shares of Common Stock issuable upon the conversion of the Series A-3 and Series A-4 Convertible Preferred Stock beneficially owned by the Continental Reporting Persons, as described in Item 5.

    7

    CUSIP No. 404139107

     

      1   NAME OF REPORTING PERSON  
             
            CONTINENTAL INSURANCE GROUP, LTD.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,639,896 *  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              3,639,896 *  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,639,896 *  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            4.4% **  
      14   TYPE OF REPORTING PERSON  
             
            CO  

      

    * Consisting of (i) 6,125 shares of Series A-3 Convertible Preferred Stock, which are convertible into 1,764,357 shares of Common Stock and (ii) 10,000 shares of Series A-4 Convertible Preferred Stock, which are convertible into 1,875,539 shares of Common Stock, as further described in Item 5.

     

    ** The aggregate percentage of shares of Common Stock for the Continental Reporting Persons and Mr. Gorzynski reported herein is based upon 81,995,850 shares of Common Stock, which reflects the sum of (i) 78,355,954 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022, plus (ii) 3,639,896 shares of Common Stock issuable upon the conversion of the Series A-3 and Series A-4 Convertible Preferred Stock beneficially owned by the Continental Reporting Persons, as described in Item 5.

    8

    CUSIP No. 404139107

     

      1   NAME OF REPORTING PERSON  
             
            CONTINENTAL GENERAL HOLDINGS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            MICHIGAN  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,639,896 *  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              3,639,896 *  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,639,896 *  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            4.4% **  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * Consisting of (i) 6,125 shares of Series A-3 Convertible Preferred Stock, which are convertible into 1,764,357 shares of Common Stock and (ii) 10,000 shares of Series A-4 Convertible Preferred Stock, which are convertible into 1,875,539 shares of Common Stock, as further described in Item 5.

     

    ** The aggregate percentage of shares of Common Stock for the Continental Reporting Persons and Mr. Gorzynski reported herein is based upon 81,995,850 shares of Common Stock, which reflects the sum of (i) 78,355,954 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022, plus (ii) 3,639,896 shares of Common Stock issuable upon the conversion of the Series A-3 and Series A-4 Convertible Preferred Stock beneficially owned by the Continental Reporting Persons, as described in Item 5.

    9

    CUSIP No. 404139107

     

    The following constitutes Amendment No. 10 to the Schedule 13D filed by the undersigned (“Amendment No. 10”). This Amendment No. 10 amends the Schedule 13D as specifically set forth herein.

    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 is hereby amended to add the following:

    On December 30, 2022, CGIC entered into a letter agreement with the Issuer (the “Letter Agreement”) whereby, until such date as the CGIC Group (as defined in the Letter Agreement) ceases to beneficially own securities of the Company in excess of 9.9% of the aggregate voting power of the outstanding shares of the Company (the “Excess Shares”), CGIC agreed to vote or cause to be voted the Excess Shares in the same manner as the holders of shares of Common Stock that beneficially own less than 10% of the outstanding shares of Common Stock at each meeting of stockholders of the Issuer and each action by written consent of the stockholders of the Issuer. The Issuer agreed to provide or cause to be provided to CGIC such information as shall reasonably be necessary or requested in order to enable CGIC to vote the Excess Shares in accordance with the Letter Agreement on a timely basis. The foregoing description of the Letter Agreement does not purport to be complete and is qualified in its entirety by reference to the Letter Agreement, which is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

    Item 7.Material to be filed as Exhibits.

    Item 7 is hereby amended to add the following exhibit:

    99.1Letter Agreement, dated December 30, 2022, by and among Continental General Insurance Company and Innovate Corp.

    10

    CUSIP No. 404139107

     

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: January 4, 2023

     

      Percy Rockdale LLC
       
      By:

    /s/ Michael Gorzynski

        Name: Michael Gorzynski
        Title: Sole Manager

     

     

      Rio Royal LLC
       
      By:

    /s/ Michael Gorzynski

        Name: Michael Gorzynski
        Title: Sole Manager

     

     

      MG Capital Management Ltd.
       
      By:

    /s/ Michael Gorzynski

        Name: Michael Gorzynski
        Title: Sole Director

     

     

     

    /s/ Michael Gorzynski

      Michael Gorzynski

     

     

      Continental General Insurance Company
       
      By:

    /s/ Michael Gorzynski

        Name: Michael Gorzynski
        Title: Executive Chair

     

     

      Continental LTC, Inc.
       
      By:

    /s/ Michael Gorzynski

        Name: Michael Gorzynski
        Title: President

     

    11

    CUSIP No. 404139107

     

      Continental Insurance Group, Ltd.
       
      By:

    /s/ Michael Gorzynski

        Name: Michael Gorzynski
        Title: President

     

     

      Continental General Holdings LLC
       
      By:

    /s/ Michael Gorzynski

        Name: Michael Gorzynski
        Title: Executive Chair

     

    12

     

    Get the next $VATE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VATE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VATE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INNOVATE Corp. Announces First Quarter 2025 Results

      - Infrastructure: DBM Global first quarter revenue of $264.9 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") System Received FDA Approval to Assess Kidney Function -- Spectrum: Expects commercial opportunities in datacasting to generate revenue by the end of the year - NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the first quarter. Financial Summary (in millions, except per share amounts)Three Months Ended March 31,  2025   2024  Increase / (Decrease)Revenue$274.2  $315.2  (13.0)%Net loss attributable to common stockholders and participating preferred stockholders$(24.8) $(

      5/6/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. to Report First Quarter 2025 Results on May 6th

      NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the first quarter 2025 on Tuesday, May 6, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "Investor

      4/16/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results

      - Infrastructure: DBM Global fourth quarter revenue of $225.7 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") system received FDA approval to assess kidney function -- Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 - NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31,  2024   2023  Increase / (Decrease)  2024   2023  Increase / (Decrease)Revenue$236.6  $361.0  

      3/31/25 4:04:24 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Financials

    Live finance-specific insights

    See more
    • INNOVATE Corp. Announces First Quarter 2025 Results

      - Infrastructure: DBM Global first quarter revenue of $264.9 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") System Received FDA Approval to Assess Kidney Function -- Spectrum: Expects commercial opportunities in datacasting to generate revenue by the end of the year - NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the first quarter. Financial Summary (in millions, except per share amounts)Three Months Ended March 31,  2025   2024  Increase / (Decrease)Revenue$274.2  $315.2  (13.0)%Net loss attributable to common stockholders and participating preferred stockholders$(24.8) $(

      5/6/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. to Report First Quarter 2025 Results on May 6th

      NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the first quarter 2025 on Tuesday, May 6, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "Investor

      4/16/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results

      - Infrastructure: DBM Global fourth quarter revenue of $225.7 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") system received FDA approval to assess kidney function -- Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 - NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31,  2024   2023  Increase / (Decrease)  2024   2023  Increase / (Decrease)Revenue$236.6  $361.0  

      3/31/25 4:04:24 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Leadership Updates

    Live Leadership Updates

    See more

    $VATE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VATE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $VATE
    SEC Filings

    See more

    $VATE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • MediBeacon Inc. Appoints Dr. Steve Miller as Chief Medical Officer

      MediBeacon expands management team as enrollment in Phase 3 study focused on kidney disease is completed ST. LOUIS, May 16, 2023 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE:VATE), today announced the appointment of Dr. Steve Miller as chief medical officer. In this role, Dr. Miller will be focused on driving a range of clinical and strategic initiatives. Dr. Miller formerly served as executive vice president and chief clinical officer at Cigna, where he led the company's clinical policy, quality, and per

      5/16/23 7:00:00 AM ET
      $VATE
      Metal Fabrications
      Industrials
    • Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

      Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary. Mr. Ferraro will be responsible for managing Catalent's global legal and compliance operations. He will be based at the company's headquarters in Somerset, New Jersey, head up the company's Legal Leadership Team, and serve on its Executive Leadership Team, reporting directly to Catalent's Executive Vice President and Chief Administrative Officer, Steven Fasman. This press release features multimedia. View the full release here: https:/

      2/13/23 8:00:00 AM ET
      $CTLT
      $PSEC
      $VATE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • INNOVATE Corp. Announces Appointment of Amy Wilkinson to the Board of Directors

      NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE), today announced the appointment of Amy Wilkinson to fill the remaining vacancy on the INNOVATE Board of Directors. "Amy brings a unique blend of management expertise and global business and policy experience, and we are confident she will help guide us in our mission to drive shareholder value across our Infrastructure, Life Sciences and Spectrum operating segments," said Avie Glazer, Chairman of INNOVATE. "Amy's leadership and strategy consulting experience advising Fortune 500 companies will be a valuable addition to our Board," said Wayne Barr, Jr., Chief Executive Officer of INNOVATE

      8/2/22 4:15:00 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Chief Financial Officer Sena Michael J. covered exercise/tax liability with 5,355 shares, decreasing direct ownership by 4% to 123,893 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      3/17/25 5:09:56 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Chief Financial Officer Sena Michael J. covered exercise/tax liability with 862 shares and was granted 12,946 shares, increasing direct ownership by 10% to 129,248 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      3/13/25 5:19:12 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Director Glazer Avram A received a gift of 4,195,804 shares and gifted 4,195,804 shares, decreasing direct ownership by 99% to 37,621 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      12/18/24 4:13:57 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Amendment: SEC Form SC 13G/A filed by INNOVATE Corp.

      SC 13G/A - INNOVATE Corp. (0001006837) (Subject)

      11/13/24 9:30:32 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Amendment: SEC Form SC 13D/A filed by INNOVATE Corp.

      SC 13D/A - INNOVATE Corp. (0001006837) (Subject)

      6/21/24 7:05:53 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • SEC Form SC 13D/A filed by INNOVATE Corp. (Amendment)

      SC 13D/A - INNOVATE Corp. (0001006837) (Subject)

      4/1/24 4:18:15 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • SEC Form 10-Q filed by INNOVATE Corp.

      10-Q - INNOVATE Corp. (0001006837) (Filer)

      5/6/25 4:16:18 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INNOVATE Corp. (0001006837) (Filer)

      5/6/25 4:09:09 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • SEC Form DEFA14A filed by INNOVATE Corp.

      DEFA14A - INNOVATE Corp. (0001006837) (Filer)

      4/28/25 4:16:15 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Interim CEO Voigt Paul bought $99,500 worth of shares (25,000 units at $3.98) (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      11/21/24 4:49:08 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Interim CEO Voigt Paul bought $166,383 worth of shares (43,785 units at $3.80), increasing direct ownership by 26% to 211,655 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      9/16/24 4:17:05 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Interim CEO Voigt Paul bought $106 worth of shares (176 units at $0.60), increasing direct ownership by 0.01% to 1,678,695 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      6/17/24 4:36:10 PM ET
      $VATE
      Metal Fabrications
      Industrials